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The aim of this review is to discuss current findings regarding the roles of miRNAs in periodontal diseases and the potential use of
saliva as a diagnosticmedium for correspondingmiRNA investigations. For periodontal disease, investigations have been restricted
to tissue samples and five miRNAs, that is, miR-142-3p, miR-146a, miR-155, miR-203, and miR-223, were repeatedly validated in
vivo and in vitro by different validation methods. Particularly noticeable are the small sample sizes, different internal controls, and
different case definitions of periodontitis in in vivo studies. Beside of that, the validated miRNAs are associated with inflammation
and therefore with various diseases. Furthermore, several studies successfully explored the use of salivary miRNA species for the
diagnosis of oral cancer. Different cancer types were investigated and heterogeneous methodology was used; moreover, no overlap
of results was found. In conclusion, fivemiRNAs have consistently been reported for periodontitis; however, their disease specificity,
detectability, and expression in saliva and their importance as noninvasivemarkers are questionable. In principle, a salivarymiRNA
diagnosticmethod seems feasible.However, standardized criteria and protocols for preanalytics,measurements, and analysis should
be established to obtain comparable results across different studies.
1. Introduction
MicroRNAs (miRNAs) are endogenous ∼22 nt RNAs that
play important regulatory roles in animals and plants by
targeting mRNAs for cleavage or translational repression [1].
Many multifarious investigations regarding miRNAs have
demonstrated their essential roles in physiological and patho-
logical processes in the immune response [2]. Additionally,
miRNAs likely contribute to development and progression of
systemic diseases, such as cancer [3] and vascular disease [4].
Consequently, there is considerable interest in use ofmiRNAs
as not only diagnostic markers but also potential therapeutic
targets for various diseases [5]. In particular, the roles of
miRNAs in oral cancer and precancer have been investigated.
MiRNA expression appears to differ between healthy tissue
and squamous cell carcinoma tissues of the oral cavity, which
is discussed in an existing review [6]. Furthermore, some
investigations have linked precancerous lesions and their risk
of becoming malignant to changes in miRNA expression [7].
Furthermore,miRNAs are associatedwith bacterial infec-
tions [8] and, thus, are most likely associated with infectious
diseases of oral cavity, for example, dental caries, endodontic
infections, and periodontitis. Kim et al. (2015), however,
already give an overview of current findings regarding dental
disease, including periodontal disease and oral cancer. Kim
et al. (2015) also mentioned limitations of current diagnostic
and potential benefit of salivarymiRNAdiagnostic [9].This is
the reason to discuss the roles of miRNAs in periodontal dis-
eases. As of now, only a few in vitro and in vivo investigations
regarding these roles are available. A recent review article
demonstrated potential roles of miRNAs during periodontal
inflammation, showing the considerable role of them in
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periodontitis [10]. Thereby, different roles and mechanisms
are shown and a very comprehensive overview on molecular
pathways is given; however, methodology was only discussed
between selected studies.
As mentioned above, an interesting approach is the
analysis of miRNA species in saliva. High quality miRNAs
were shown to be detectable in saliva [11], and the possibility
of their usage in oral cancer detection appears to have a
high potential for future diagnostics [12]. This noninvasive
approach could be relevant for further diseases of the oral
cavity. Nevertheless, the potential usage of miRNA as salivary
markers for periodontal diseases was already not discussed
yet. As shown for oral cancer, using miRNA for noninvasive
diagnostics seems feasible [12] and could therefore serve as
a salivary marker for periodontitis. The potential is high,
so maybe recent indispensable invasive diagnostics or X-ray
could become avoided by salivary miRNA diagnostic in the
future and an early diagnosis might help to prevent bone and,
in conclusion, tooth loss.
Nevertheless, despite of the huge potential,many different
results are available, both for salivary oral cancer diagnostics
and for analysis of periodontal tissue. Accordingly, it is
questionable if the reasons are methodological differences
between the studies or maybe if the usage of miRNAs in
general is unsuitable.
Therefore, this review article shows current results of in
vitro and in vivo studies regarding periodontal diseases as
well as results of selected current studies dealing with salivary
miRNAs for oral cancer detection. The aim was to detect
promising future perspectives, but also current challenges
regarding this issue. In particular, methodological aspects
are focused to detect potential limitations of miRNAs as
noninvasive markers for periodontitis.
2. Methods
2.1. Search Strategy. Our literature research was performed
using the online database PubMed (http://www.ncbi.nlm.nih
.gov/pubmed). To obtain a broad overview of the available
theme-specific publications, we used different keywords for
our search. We used “miRNA AND periodontitis” as key-
words to obtain results for periodontal diseases. We used
“miRNA AND saliva AND oral disease” and “miRNA AND
saliva AND cancer” as keywords to obtain relevant articles
for noninvasive possibilities, that is, the use of saliva to
investigate miRNAs in diseases of the oral cavity. Then, the
reference lists of relevant articles were searched for further
results. To interpret the results, relevant publications were
searched and analyzed critically. Neither a meta-analysis nor
other statistical comparisons of existing data were performed.
2.2. Selection Criteria. Only current full-length articles in
English language were included. The results were verified
for their relevance. The following selection criteria were
defined: miRNA investigations for in vitro and in vivo studies
examining periodontal disease. Additionally, in vivo human
investigations regarding salivary miRNA analysis in oral
cancer and precancer were included.
2.3. Selection Process. Following the literature search, all ref-
erences were limited to relevant publications. In vivo peri-
odontal disease investigations that did not address peri-
odontal tissue were excluded. Salivary diagnostic studies that
did not explicitly concentrate on miRNAs were excluded,
and only investigations for oral cancer and precancer were
included.
3. Results
3.1. Periodontal Diseases
3.1.1. In Vitro. Eight in vitro studies, which detected different
miRNAs, were included for periodontal disease (Table 1).
Nahid et al. (2011) examined the expression of cytokines
associated with inflammation and differences in expression
of cytokines and miRNA during infection with live and heat-
killed bacteria in THP-1 monocytes. They demonstrated that
expression of miR-146a is associated with infections caused
by periodontal pathogenic bacteria in vitro [13]. Another
study indicated that miR-146a is significantly overexpressed
in THP-1 cells after stimulation with LPS from P.g. [14].
Furthermore, miR-146a was shown to be a negative regulator
of TLR-NF𝜅B pathway in human periodontal ligament cells
after P. gingivalis LPS stimulation, therefore being involved
in inflammatory response [15]. Moreover, expression of miR-
146a and miR-146b-5p in human gingival fibroblasts after
stimulation with P.g. LPS was also investigated in a study by
Xie et al. (2013). They demonstrated that expression of these
miRNAs significantly increased upon LPS stimulation and
concluded that miR-146 could work as a negative regulator
of inflammation in periodontal disease [16]. Differential
expression of miR-146a and miR-155 in dental pulp and in
gingival and periodontal fibroblasts after stimulation with
LPS from Escherichia coli was also reported. The increased
expression of miR-146a was the highest in gingival fibroblasts
and decreased expression of miR-155 was only significant
in gingival fibroblasts [17]. Naqvi et al. (2014) showed dif-
ferent expressions of miR-146a. In this in vitro study THP-
1 macrophages that were stimulated with LPS from Aggre-
gatibacter actinomycetemcomitans, P.g., and also P.g. grown
on cigarette smoke extract were examined. The different
LPS caused both some identical and also varied expressions
of miRNAs in human macrophages. Moreover, LPS from
P.g. grown on cigarette smoke extract compared to LPS
from unaffected P.g. caused differential miRNA expression,
particularly that of miR-29b in human macrophages [18].
Results reported in other two studies weremore heteroge-
nous: Ouhara et al. (2014) demonstrated upregulated miR-
584 in human gingival epithelial cells after stimulation with
P.g. [19]. Furthermore, Moffat and Lamont (2011) focused
on miR-203 expression in gingival epithelial cells stimulated
with P.g. In this study, 14 miRNAs displayed significant chan-
ges in expression after exposure to P.g.; of these miRNAs,
miR-203 was examined in detail and showed higher expres-
sion in tissues after P.g. stimulation [20].
3.1.2. In Vivo Animal. Nahid et al. (2011) investigated expres-
sion of miR-146a, miR-132, and miR-155 in spleens and
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Table 2: Criteria for patient selection.
Author and year PD CAL BOP Radiographic bone loss
Healthy Periodontitis Healthy Periodontitis Healthy Periodontitis Healthy Periodontitis
Stoecklin-Wasmer et al. 2012 [24] ≤4mm >4mm ≤2mm ≥3mm negative positive n.i. n.i.
Xie et al. 2011 [22] <3mm ≥5mm <1mm ≥3mm n.i. ∗ No Yes
Lee et al. 2011 [21] ≤3mm >5mm none >3mm ∗∗ n.i. No Yes
Perri et al. 2012 [26] ≤4mm >5mm n.i. n.i. Negative Positive No Yes
Ogata et al. 2014 [23] n.i. ≥6mm n.i. >6mm n.i. Positive n.i. n.i.
Motedayyen et al. 2015 [25] <3mm n.i. <3mm n.i. n.i. n.i. No n.i.
Kalea et al. 2015 [27] n.i. >5mm n.i. ∗ ∗ ∗ n.i. n.i. n.i. ∗ ∗ ∗
PD: pocket depth; CAL: clinical attachment loss; BOP: bleeding on probing; n.i.: no information. ∗GI > 1; ∗∗BOP in whole gingiva < 10%, ∗∗∗bone loss > 30%.
maxillae of ApoE−/− mice after infection with periodontal
pathogenic bacteria P.g., Treponema denticola and Tannerella
forsythia. MiR-146a primarily showed a significant increase
in both maxillae and spleens, while miR-132 and miR-155
showed only minor changes [13].
3.1.3. In Vivo Human. Seven in vivo studies investigating
differential expression of miRNAs in human tissue samples
were included (Table 1). In particular, Lee et al. (2011) com-
pared the expression of inflammatorymiRNAs in healthy and
inflamed periodontal tissue. Microarray analysis indicated
that expression of six miRNAs was upregulated more than
eightfold and that expression of 22 miRNAs increased more
than fourfold in periodontal disease tissue compared with
healthy tissue. Of these miRNAs, six could be validated by
qRT-PCR [21]. A similar investigation considered miRNA
profiles of healthy and inflamed gingival tissues. Microarray
analysis of healthy and inflamed gingival tissues indicated
that expression of five miRNAs was upregulated more than
fivefold, 85 miRNAs, twofold to fivefold. Moreover, expres-
sion of 34 miRNAs was downregulated twofold to fivefold in
inflamed tissue. 12 miRNAs were validated by qRT-PCR [22].
A study of Japanese patients identified 17 upregulated and
22 downregulated miRNAs; six were selected for validation
[23]. A further investigation also detected differentialmiRNA
expression by microarray analysis, wherein 91 upregulated
and 68 downregulated miRNAs were found. Six miRNAs
were validated, and potential target genes were investigated
[24]. Furthermore, Motedayyen et al. (2015) showed a posi-
tive relationship betweenmiR-146a and clinical parameters in
patients with chronic periodontitis [25].Thus,manymiRNAs
with differential expression as detected by microarray analy-
sis have not been validated by qRT-PCR; these miRNAs will
not be discussed (Table 1).
Additionally, two studies investigated the roles of miR-
NAs in periodontal disease in association with systemic
factors and disease; thus, differential expression of miRNAs
between obese periodontitis patients and nonobese perio-
dontitis patients was examined. However, different, nonover-
lappingmiRNAs were reported in each investigation [26, 27].
Notably, criteria for patient selection and for classification
of healthy and diseased patients were similar across all
studies. However, differences exist between investigations
in defining periodontal health and periodontitis (Table 2).
Additionally the number of study participants for in vivo
investigations varied enormously between studies with ten
patients or less for each group in most cases (Table 1). Like-
wise, methodological approach was similar across studies:
microarray based technology was often used to screen and
identify miRNAs with differential expression, and qRT-PCR
was used for subsequent validation of top-hits. However,
detailed methods were different; thus, for example, different
miRNA isolation methods were used. Also differences in sta-
tistical analysis are conspicuous, especially internal controls
that distinguish between the studies (Table 1).
3.2. MiRNA Detection in Saliva as a Noninvasive Diagnostic
Tool. Nine investigations were included that illustrate the
potential of saliva as noninvasive diagnostic tool for miRNA
analyzes. We focused on salivary miRNA species analysis as a
diagnostic method for oral cancer and precancer detection,
because no results of appropriate dental and periodontal
disease investigations could be found. Six of included studies
examined oral squamous cell carcinoma, one precancerous
lesions, one esophageal cancer, and one tumor of parotid
gland. Park et al. (2009) showed presence of miRNA species
in whole saliva and in saliva supernatants and described
differential expression of miR-125a and miR-200a between
cases and controls. Besides that stability of exogenous (miR-
124a) and endogenous (miR-191) miRNA in saliva was
also examined in this study, and endogenous miRNA was
shown to have higher stability than exogenous miRNA
[28]. Another investigation found that miR-9, miR-191, and
miR-134 appeared to be potential markers for noninvasive
diagnosis of oral squamous cell carcinoma using saliva.
Additionally, this study describes a reliable isolation method
for miRNAs from even small volumes of saliva [29]. In a
study by Hung et al. (2016) salivary miRNAs, specifically
miR-31 and miR-21 were investigated in oral premalignant
disorders, particularly showing miR-31 to be a sufficient
marker for high risk disorders and malignant transformation
[30]. Also Liu et al. (2012) examined miR-31, and its expres-
sion in saliva was compared with its expression in plasma;
thereby, a correlation could be shown. These authors also
observed a decrease in expression of miR-31 after surgical
resection of primary tumor [31]. Similarly, Duz et al. (2016)
reduced miR-139-5p expression in patients with tongue
carcinoma and normalization after surgical treatment [32].
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In a study investigating expression of salivary miRNAs in
premalignant lesions of oral cavity, a correlation was found
between deregulated miRNA expression in tissue and saliva,
although miRNA concentrations in saliva were lower [33].
A further investigation compared expression of miRNA in
saliva between patients with oral squamous cell carcinoma,
patients with oral squamous cell carcinoma in remission,
patients with oral lichen planus, and a healthy control group.
In addition to differences in miRNA expression between the
groups, miR-27b was significantly overexpressed in saliva
of patients with oral squamous cell carcinoma. Further-
more, completely different profiles of miRNAs could be
found in cancerous tissues compared to biological fluids
[34]. Additionally, another study found miRNA-184 to have
the potential to distinguish between OSCC and potentially
malignant disorders [35].
In addition, altered miRNA expression in saliva was also
verified for esophageal cancer [36] and parotid gland tumors
[37]. Their methodologies are shown in Table 3. In prin-
ciple, methods of measurement (microarray, qRT-PCR) are
similar between the studies. Remarkable differences could
be found regarding form of saliva, extraction methods,
statistical analysis, and internal controls. The number of
study participants was already higher than for periodontitis.
However, heterogeneous groups sizes with partly seven or
eight patients each group [33, 34] and partly 50 patients and
more each group [28, 29] were investigated (Table 3).
4. Discussion
Several studies investigating putative role of miRNAs in
periodontal diseases have been performed; however, spec-
trum of miRNAs identified was substantially heterogeneous.
Both in vitro and in vivo investigations were performed for
periodontal disease, and five miRNAs, that is, miR-142-3p,
miR-146a, miR-155, miR-203, and miR-223, were validated
in more than one study. Accordingly, we can conclude that
these miRNAs may play important role and thus could
become potential markers for periodontal disease. However,
majority of identified miRNA species differed significantly
across studies (Table 1).
MiR-146a and miR-155 were dominant in in vitro studies.
Otherwise, these miRNAs have also been identified in other
inflammatory diseases and various cancers. MiR-146a seems
to play a role in multifarious diseases and its function in
bacterial infections has already been discussed [38]. MiR-155
has also been mentioned [39]. LPS may have a substantial
effect on the expression of miR-146a and miR-155 [40].
Consequently, their altered expression during periodontal
disease is not surprising because bacterial virulence factors
such as LPS are relevant in pathogenesis of periodontitis [41].
These miRNAs are associated with many other inflammatory
diseases, which might be indicative of a limited specificity.
Additionally, miR-142-3p is associated with inflammation
and LPS exposure [42, 43]. MiR-203 may also play an impor-
tant role in inflammation and correlate with LPS exposure
[44]. Interestingly, miR-203 expression is associated with
immune reaction of skin [45, 46]. MiR-203 expression in
keratinocytes is important; therefore, this miRNA may also
be involved in gingivitis and periodontitis as determined by
its effect on gingival keratinocytes. Finally,miR-223 also plays
an important role in inflammation and LPS exposure [47].
Accordingly, correlations between these five miRNAs and
periodontal disease are possible. Interestingly, these miRNAs
appear to play a role in oral cancer. Thus, their roles in
periodontal disease should be further examined (Table 4)
as it might indicate a link between periodontitis and head
and neck squamous cell carcinoma (HNSCC). Figure 1 shows
a summary of the interactions between periodontitis and
HNSCC [48], and some potentially involvedmiRNAs. In this
context, miR-29b, which showed an in vitro correlation with
LPS from P.g. grown on cigarette smoke extract [18], has also
been examined for oral cancer [49]. These findings raise the
question if these miRNAs could serve as diagnostic markers
for periodontal diseases or simply reflect an increased inflam-
matory state associated with various diseases.
Another problem is the great diversity of results. Al-
though many miRNAs were found, convergence between
the investigations, particularly in vivo, is small, resulting
in conflicting conclusions. Reasons for differences between
investigations of periodontal disease may differ. On the one
hand, small variety in patient selection and different clinical
procedures potentially causes these differences (Table 2). For
future studies an evident graduation, for example, Page and
Eke 2007, should be used for standardization [50]. On the
other hand, variations in methods used for miRNA detection
could play a crucial role (Table 3). A comparison of methods
used suggests that miRNA detection procedures were quite
similar. However, many differences in detailed procedures
are evident. Using microarray and quantitative RT-PCR for
analyzing and validating miRNAs are essential components
of most investigations. However, detailed procedures for
methods primarily differ, so several arrays from different
manufacturing companies were performed. Importantly, dif-
ferences in all of chosen criteria can be found between the
investigations. Besides variations in statistical analyses it is
important that internal controls differed in most cases.
Another aspect that could be crucial for the varying
results is the small number of study participants. One study
even investigated only three healthy and three diseased
individuals [23]. A large group of 86 patients was selected
only once [24]. The use of small sample sizes increases
vulnerability to a range of errors and biases and may be a
major reason for heterogeneous study results and potential
false-positive findings. Similar issues were faced in early
human genetic association studies, where many of reported
genotype-phenotype associations could not be replicated in
subsequent studies [51, 52]. Today, replication of initial find-
ings in second cohort is considered essential for establishing
the credibility of a genotype-phenotype association [53] and
similar approaches could be adopted for studies reporting
associations between miRNAs and diseases. Clearly, complex
reason for differences in results exists. Different methods,
clinical criteria, small groups of patients, and small specificity
of miRNAs for periodontal disease could be causal complex.
In summary, comparability of results for the roles of
miRNAs in periodontal disease is questionable. Potential
8 BioMed Research International
Ta
bl
e
3:
C
om
pa
ris
on
of
m
et
ho
ds
fo
rs
al
iv
ar
y
m
iR
N
A
di
ag
no
sis
.
Au
th
or
an
d
ye
ar
N
um
be
ro
fs
tu
dy
pa
rt
ic
ip
an
ts
Fo
rm
of
sa
liv
a
m
iR
N
A
ex
tr
ac
tio
n
m
et
ho
d
D
et
ec
tio
n
of
m
iR
N
A
pr
ofi
le
Va
lid
at
io
n
In
te
rn
al
co
nt
ro
l
St
at
ist
ic
al
an
al
ys
is
Po
te
nt
ia
lm
ar
ke
r
fo
rc
ar
ci
no
m
a
Pa
rk
et
al
.2
00
9
[2
8]
50
or
al
sq
ua
m
ou
s
ce
ll
ca
rc
in
om
a
(O
SC
C)
pa
tie
nt
s
an
d
50
he
al
th
y
m
at
ch
ed
co
nt
ro
l
su
bj
ec
ts
U
ns
tim
ul
at
ed
w
ho
le
sa
liv
aa
nd
sa
liv
a
su
pe
rn
at
an
t
m
irV
an
a™
m
iR
N
A
Is
ol
at
io
n
Ki
t
(A
m
bi
on
)
D
N
A-
fre
e™
(A
m
bi
on
)
RT
-p
re
am
p-
qP
CR
(A
pp
lie
d
Bi
os
ys
te
m
s)
(i)
RT
-p
re
am
p-
qP
CR
(A
pp
lie
d
Bi
os
ys
te
m
s)
(ii
)F
ou
r-
pl
ex
RT
-p
re
am
p-
qP
CR
fo
r
m
iR
-1
42
-3
p,
m
iR
-2
00
a,
m
iR
-1
25
a,
an
d
m
iR
-9
3.
U
6
sn
RN
A
M
an
n-
W
hi
tn
ey
𝑈
te
st
m
iR
-1
25
a
m
iR
-2
00
a
Li
u
et
al
.2
01
2
[3
1]
45
pa
tie
nt
sw
ith
O
SC
C
an
d
10
pa
tie
nt
w
ith
or
al
ve
rr
uc
ou
s
le
uk
op
la
ki
a
24
he
al
th
y
in
di
vi
du
al
s
U
ns
tim
ul
at
ed
sa
liv
a
su
pe
rn
at
an
t
m
irV
an
aP
A
RI
S
Is
ol
at
io
n
ki
t
(A
m
bi
on
)
D
N
as
ed
ig
es
tio
n
Ta
qM
an
m
iR
N
A
as
sa
y
sy
ste
m
(A
pp
lie
d
Bi
os
ys
te
m
s)
Ta
qM
an
m
iR
N
A
as
sa
y
sy
ste
m
(A
pp
lie
d
Bi
os
ys
te
m
s)
m
iR
-1
6
M
an
n-
W
hi
tn
ey
te
st,
W
ilc
ox
on
m
at
ch
ed
pa
irs
te
st,
an
d
lin
ea
r
re
gr
es
sio
n
an
al
ys
is,
re
ce
iv
er
-o
pe
ra
tin
g
ch
ar
ac
te
ris
tic
sR
O
C
an
al
ys
is
m
iR
-3
1
Ya
ng
et
al
.2
01
3
[3
3]
8
pr
og
re
ss
in
g
LG
D
le
uk
op
la
ki
as
7
no
np
ro
gr
es
sin
g
LG
D
le
uk
op
la
ki
as
7
he
al
th
y
vo
lu
nt
ee
rs
U
ns
tim
ul
at
ed
sa
liv
a
RN
ea
sy
M
ic
ro
Ki
t
(Q
ia
ge
n)
Ta
qM
an
®l
ow
de
ns
ity
ar
ra
y
(T
LD
A
)
qR
T-
PC
R
sy
ste
m
(A
pp
lie
d
Bi
os
ys
te
m
s)
we
re
us
ed
fo
rg
lo
ba
l
m
iR
ex
pr
es
sio
n
an
al
ys
is
in
tis
su
e
sa
m
pl
es
Ta
qM
an
M
ic
ro
RN
A
As
sa
y
(A
pp
lie
d
Bi
os
ys
te
m
s)
RN
U
6
Ra
nd
om
va
ria
nc
e
𝑡
-te
st,
Be
nj
am
in
i-H
oc
hb
er
g
fa
lse
di
sc
ov
er
y
ra
te
(F
D
R)
m
et
ho
d,
M
an
n-
W
hi
tn
ey
𝑈
te
st,
St
ud
en
t’s
𝑡
-te
sts
(tw
o-
sid
ed
)
m
iR
-1
0b
,m
iR
-1
45
,
m
iR
-9
9b
,m
iR
-7
08
,
m
iR
-1
81
c,
m
iR
-3
0e
,
m
iR
-6
60
,m
iR
-1
97
Xi
ee
ta
l.
20
13
[3
6]
39
pa
tie
nt
sw
ith
es
op
ha
ge
al
ca
nc
er
an
d
19
he
al
th
y
co
nt
ro
ls
St
im
ul
at
ed
w
ho
le
sa
liv
aa
nd
su
pe
rn
at
an
t
m
irV
an
aP
A
RI
S
Ki
t(
A
m
bi
on
)
7w
ho
le
sa
liv
as
am
pl
es
fo
rE
C
gr
ou
p
an
d
3
fo
rh
ea
lth
y
gr
ou
p
fo
r
A
gi
le
nt
m
ic
ro
ar
ra
y
11
.0
(A
gi
le
nt
Te
ch
no
lo
gi
es
)
RT
-q
PC
R
SY
BR
Pr
em
ix
Ex
Ta
q
(T
aK
aR
a)
m
iR
-1
6
M
an
n-
W
hi
tn
ey
𝑈
te
st
or
th
eK
ru
sk
al
l-W
al
lis
𝐻
te
st,
𝜒
2
te
st,
re
ce
iv
er
-o
pe
ra
tin
g
ch
ar
ac
te
ris
tic
sR
O
C
cu
rv
es
,S
pe
ar
m
an
’s
co
rr
el
at
io
n
te
st
m
iR
-1
0b
,m
iR
-1
44
,
m
iR
-4
51
(in
w
ho
le
sa
liv
a)
m
iR
-1
0b
∗
,
m
iR
-1
44
,m
iR
-2
1,
m
iR
-4
51
(in
sa
liv
a
su
pe
rn
at
an
t)
M
at
se
et
al
.
20
13
[3
7]
38
pa
tie
nt
sw
ith
m
al
ig
na
nt
an
d
29
w
ith
be
ni
gn
pa
ro
tid
gl
an
d
tu
m
or
s
W
ho
le
sa
liv
a
an
d
su
pe
rn
at
an
t
m
irV
an
aP
ar
is
ki
t
(A
m
bi
on
)
D
N
as
eI
(Q
ia
ge
n)
Ta
qM
an
H
um
an
M
ic
ro
RN
A
Ca
rd
s
(A
pp
lie
d
Bi
os
ys
te
m
s)
Ta
qM
an
M
ic
ro
RN
A
as
sa
ys
(A
pp
lie
d
Bi
os
ys
te
m
s)
Ta
qM
an
m
ic
ro
RN
A
as
sa
ys
(A
pp
lie
d
Bi
os
ys
te
m
s)
U
6
sn
RN
A
W
ilc
ox
on
ra
nk
-s
um
te
st,
RO
C
cu
rv
es
hs
a-
m
iR
-3
74
,
hs
a-
m
iR
-2
22
,
hs
a-
m
iR
-1
5b
,
hs
a-
le
t-7
g,
hs
a-
m
iR
-1
32
,
m
m
u-
m
iR
-1
40
-5
p
BioMed Research International 9
Ta
bl
e
3:
C
on
tin
ue
d.
Au
th
or
an
d
ye
ar
N
um
be
ro
fs
tu
dy
pa
rt
ic
ip
an
ts
Fo
rm
of
sa
liv
a
m
iR
N
A
ex
tr
ac
tio
n
m
et
ho
d
D
et
ec
tio
n
of
m
iR
N
A
pr
ofi
le
Va
lid
at
io
n
In
te
rn
al
co
nt
ro
l
St
at
ist
ic
al
an
al
ys
is
Po
te
nt
ia
lm
ar
ke
r
fo
rc
ar
ci
no
m
a
M
om
en
-H
er
av
i
et
al
.2
01
4
[3
4]
9
O
SC
C
pa
tie
nt
s
be
fo
re
tre
at
m
en
t,
8
pa
tie
nt
sw
ith
O
SC
C
in
re
m
iss
io
n,
8
pa
tie
nt
sw
ith
O
LP
,
an
d
9
he
al
th
y
co
nt
ro
ls
U
ns
tim
ul
at
ed
w
ho
le
sa
liv
a
RN
ea
sy
ki
t
(Q
ia
ge
n)
m
ul
tip
le
xe
d
N
an
oS
tr
in
g
nC
ou
nt
er
m
iR
N
A
ex
pr
es
sio
n
as
sa
y
(N
an
oS
tr
in
g
Te
ch
no
lo
gi
es
)
Ta
qM
an
M
ic
ro
RN
A
as
sa
y
(A
pp
lie
d
Bi
os
ys
te
m
s)
m
iR
N
A-
19
1
1-w
ay
an
al
ys
is
of
va
ria
nc
e,
fo
llo
w
ed
by
a2
-ta
ile
d
M
an
n-
W
hi
tn
ey
𝑈
te
st
or
St
ud
en
t’s
𝑡
-te
st,
RO
C
cu
rv
es
an
al
ys
is
m
iR
-2
7b
Sa
la
za
re
ta
l.
20
14
[2
9]
5
H
N
SC
C
pa
tie
nt
s,
5
he
al
th
y
co
nt
ro
ls
fo
re
xp
re
ss
io
n
an
al
ys
is
56
H
N
SC
C
pa
tie
nt
s,
56
he
al
th
y
co
nt
ro
ls
fo
r
va
lid
at
io
n
U
ns
tim
ul
at
ed
w
ho
le
sa
liv
a
Q
IA
zo
ll
ys
is
re
ag
en
t(
Q
ia
ge
n)
N
uc
le
oS
pi
n
m
iR
N
A
ki
t
(M
ac
he
re
y-
N
ag
el)
m
iS
cr
ip
t™
m
iR
N
A
PC
R
ar
ra
ys
(Q
ia
ge
n)
RT
-q
PC
R
m
iS
cr
ip
t
SY
BR
gr
ee
n
PC
R
m
as
te
r
m
ix
(Q
ia
ge
n)
SN
O
RD
96
A
M
an
n
W
ith
ne
y
𝑈
-te
st,
RO
C
cu
rv
es
,
W
ilc
ox
on
ra
nk
su
m
te
st,
Bo
nf
er
ro
ni
m
et
ho
d
m
iR
-9
,m
iR
-1
34
,
m
iR
-1
91
Za
hr
an
et
al
.
20
15
[3
5]
20
he
al
th
yc
on
tro
ls,
40
po
te
nt
ia
lly
m
al
ig
na
nt
di
so
rd
er
s,
20
O
SC
C,
20
re
cu
rr
en
ta
ph
th
ou
s
sto
m
at
iti
s
U
ns
tim
ul
at
ed
sa
liv
a
su
pe
rn
at
an
t
m
iR
N
ea
sy
se
ru
m
/p
la
sm
a
ex
tr
ac
tio
n
ki
t
(Q
ia
ge
n)
—
RT
-q
PC
R
SY
BR
gr
ee
n
PC
R
ki
t(
Q
ia
ge
n)
SN
O
RD
68
O
ne
-w
ay
A
N
O
VA
,
𝐹
-te
st,
D
un
ne
tt
𝑡
-te
st,
Sc
he
ffe
’s
m
ul
tip
le
co
m
pa
ris
on
,
tw
o-
ta
ile
d
te
sts
m
iR
-2
1,
m
iR
-1
84
,
m
iR
-1
45
D
uz
et
al
.2
01
6
[3
2]
50
sa
liv
as
am
pl
es
fro
m
25
TS
CC
pa
tie
nt
s(
on
ce
pr
io
rt
o
an
d
on
ce
aft
er
su
rg
ic
al
tre
at
m
en
t)
U
ns
tim
ul
at
ed
sa
liv
a
su
pe
rn
at
an
t
m
irV
an
aP
A
RI
S
ki
t(
A
m
bi
on
)
8
sa
m
pl
es
(4
TS
CC
pa
tie
nt
s4
he
al
th
y
co
nt
ro
l)
us
in
g
A
gi
le
nt
8
×
60
K
hu
m
an
V
19
m
iR
N
A
m
ic
ro
ar
ra
ys
Ta
qM
an
M
ic
ro
RN
A
as
sa
y
(A
pp
lie
d
Bi
os
ys
te
m
s)
RN
U
6b
Tw
o-
sid
ed
St
ud
en
t’s
𝑡
-te
st,
Re
ce
iv
er
op
er
at
in
g
ch
ar
ac
te
ris
tic
(R
O
C)
cu
rv
es
,9
5%
co
nfi
de
nc
ei
nt
er
va
l
(C
I)
m
iR
-1
39
-5
p
H
un
g
et
al
.
20
16
[3
0]
20
pa
tie
nt
sw
ith
or
al
po
te
nt
ia
lly
m
al
ig
na
nt
di
so
rd
er
s,
24
he
al
th
y
in
di
vi
du
al
s
U
ns
tim
ul
at
ed
sa
liv
a
su
pe
rn
at
an
t
m
irV
an
aP
A
RI
S
iso
la
tio
n
ki
t
(A
m
bi
on
)
—
Ta
qM
an
m
ic
ro
RN
A
as
sa
y
(A
pp
lie
d
Bi
os
ys
te
m
s)
m
iR
-1
6
U
np
ai
re
d
te
st,
RO
C
cu
rv
es
,K
ap
la
n-
M
ei
er
m
et
ho
d,
lo
g-
ra
nk
te
st,
C
ox
pr
op
or
tio
na
l
ha
za
rd
m
od
el
m
iR
-2
1
m
iR
-3
1
RN
A
ex
tr
ac
tio
n
an
d
iso
la
tio
n
m
et
ho
ds
ar
el
ist
ed
.Th
ep
ro
of
of
qu
al
ity
an
d
qu
an
tit
ya
nd
qu
al
ity
as
su
ra
nc
ea
re
sh
ow
n
as
im
po
rt
an
tq
ua
lit
yc
rit
er
ia
to
dr
aw
co
nc
lu
sio
ns
re
ga
rd
in
gt
he
re
pr
od
uc
ib
ili
ty
an
d
sta
nd
ar
di
za
tio
n
of
th
ei
nv
es
tig
at
io
ns
.F
ur
th
er
m
or
e,
m
et
ho
ds
fo
rm
iR
N
A
pr
ofi
lin
ga
nd
m
iR
N
A
va
lid
at
io
n
ar
el
ist
ed
.I
n
ad
di
tio
n,
th
en
um
be
ro
fs
tu
dy
pa
rt
ic
ip
an
ts
is
pr
ov
id
ed
to
dr
aw
co
nc
lu
sio
ns
re
ga
rd
in
gt
he
va
lid
ity
of
th
er
es
ul
ts.
Th
ef
or
m
of
sa
liv
ai
sa
lso
lis
te
d.
10 BioMed Research International
Table 4: Comparison of miRNas frequently mentioned in connection with periodontal disease with results from selected oral cancer and
precancer investigations.
Kozaki et al.
2008 [63]
Park et al.
2009 [28]
Cervigne et al.
2009 [64]
Scapoli et al.
2010 [65]
Lajer et al.
2011 [66]
Lundegard et al.
2015 [56]
miR-146a X X X X
miR-155 X X X
miR-203 X X
miR-142-3p X X
miR-223 X X
Each miRNA that was validated in the context of periodontal disease was also mentioned in investigations for cancer and precancer of the oral cavity. This
table provides a small exemplary overview. Consequently, even more studies with similar results are not shown here.
Chronic
periodontitis
Keratinocytes
Bacteria 
(i) Endotoxin (LPS) 
(ii) Enzymes (proteases, 
collagenases, fibrinolysin,
phospholipase A)
(iii) Metabolic by-products
(H2S, NH3, fatty acids) 
HNSCC
miR-203 miR-203
miR-142-3p
miR-146a
miR-155
miR-223
miR-142-3p
miR-146a
miR-155
miR-223
miR-29b miR-29b
Inflammation
(i) Cytokines,
(ii) Growth factors
(iii) Prostaglandins
(iv) Enzymes (iNOS, 
COX-2, MMP)
(v) Reactive oxygen 
species (hydrogen 
peroxide, oxy
(vi) Reactive nitrogen 
species (nitric oxides)
(vii) Reactive lipids
 and metabolites 
(malondialdehyde, 4-
hydroxy-2-nonenal)
radicals)
chemokines
Mucosal injury
(i) Susceptibility to HPV 
and other viral infections
(ii) Penetration of other
carcinogens (tobacco,
alcohol, diet . . . )
Figure 1: Model for the relationship among chronic periodontitis, HNSCC (modif. Han et al. 2014 [48]) and potential miRNAs that may be
involved in the corresponding processes.
BioMed Research International 11
candidate miRNAs as promising markers of periodontal
disease do not appear to be specific for periodontitis.
Use of salivary miRNAs as noninvasive diagnostic mark-
ers has been studied in context of oral cancer, precancer,
esophageal cancer, and parotid gland cancer so far. Again,
reported results of these studies were quite divergent with
little overlap in identified miRNA species. Importantly, these
investigations used similar methods for miRNA detection in
periodontal tissue and saliva; however, detailed methods are
quite different (Tables 1 and 3).
In principle, detectability of miRNAs in saliva seems
certainly possible, so, for example, a current study was able to
detect noncoding RNAs in saliva: 127 to 418 miRNAs could
be detected in each sample of human cell free saliva, with
miR-223-3p being most abundant [54]. Interestingly, miR-
223 is also found in periodontal tissue. Different studies have
examined saliva to identify miRNAs as potential markers
for oral cancer and precancer and report remarkably diverse
results (Table 3). Strangely, basic principles of investigations
were similar, but different internal controls, methods for
miRNA isolation, statistical analysis, and forms of saliva
(stimulated/unstimulated, whole saliva/supernatant) were
chosen. Notably, number of study participants is already
higher in these investigations than in studies of periodontitis,
but also heterogeneous with partly small group sizes (Tables
1 and 3). In addition, form of saliva may play an important
role, especially whether stimulated or unstimulated saliva is
used may be relevant as well as exact procedure for obtaining
saliva and criteria for patient selection. Furthermore, lack of
stability of exogenous miRNAs in saliva may result in quick
changes of miRNA concentrations from bacteria and inflam-
matory reactions [28]. Potential concentrations ofmiRNAs in
body fluids in exosomes could also affect their detectability
in human saliva samples [55]. Beside of that, however, it was
mentioned that there are vesicle-free noncoding RNAs in
saliva [54]. Furthermore, it is questionable whether identified
miRNAs from tissue investigations are also potential markers
for salivary diagnostic methods. The finding of completely
different miRNA expression between cancerous tissue and
body fluids [34] could be similar for periodontitis.
Detailed procedures of miRNA extraction and detection
could also be relevant. In a recent study by Lundegard et
al. (2015) expression of miR-203 was examined in whole
saliva using two different PCRmethods.The study concluded
that detecting low levels of miRNA in saliva is difficult;
more efficient extraction methods and more sensitive PCR
techniques are necessary to use saliva as a reproducible
source of miRNAs [56]. Because of differences in methods
used, it is questionable if investigations are comparable at
all. Some miRNAs may have variable expression between
different microarray, PCR, and preparation methods [57].
Reproducibility and standardization of procedure appear
relevant. Validated protocols such as those already described
[58] may help to standardize the procedures. This would
allow better reproducibility and provide more meaningful
and more comparable results. This is supported by results
of Hung et al. and Liu et al. both showing miR-31 to be a
potential marker for malignant tumor [30, 31]. As shown in
Table 3, both studies used same form of saliva, extraction,
and validation methods as well as internal controls (Table 3).
Accordingly, use of saliva for diagnosis of periodontal disease
under condition of uniform methods seems conceivable.
However, the mechanism of miRNA infiltration in saliva
during periodontal diseases must be considered. Thereby,
exosomes might play a key role in miRNA transport from
different cells into saliva [59]. In periodontal tissue, the
junctional epithelial layers might be of highest relevance in
this context.The junctional epithelium contains only few des-
mosomes and has therefore widened intercellular spaces
[60]. Accordingly, this epithelium allows transport of several
molecules between tissue and gingival crevicular fluid (GCF)
[61]. Additionally, an enlarged permeability with an increase
of GCF flow is observed during gingival and periodontal
inflammation [61]. Consequently, high amounts of miRNA
might pass the junctional epithelium, arriving GCF and thus
saliva.
If comparable results can be achieved, further investi-
gations will be of interest. For example, changes in miRNA
expression after surgical resection of a tumor, as already
described [3, 32], could become clinically useful by demon-
strating improved periodontal conditions after therapy as
well. Therefore, it could be assessed whether periodontitis
therapy was successful by analyzing expression of specific
miRNAs. Additionally, correlation between periodontitis and
systemic diseases could be illustrated by altered miRNA
expression [26, 27]. Although this topic seems to have great
potential to provide further insights regarding oral disease,
a critical view is needed. Currently, we have insufficient
knowledge regarding oral disease and the roles of miRNAs in
pathological processes. At present it is impossible to provide
a clear statement regarding real relevance and possibilities of
miRNA analysis. Nevertheless, using miRNAs to understand
oral diseases, particularly periodontitis, and potential use of
miRNAs as noninvasive markers or as therapeutic targets
could be a great approach, which justifies basic research in
any case. In conclusion, we can confirm unequivocally that
salivary miRNA diagnosis for periodontal disease is a revolu-
tionary idea. However, considering that additional investiga-
tions and standardized methods are required, possibilities of
exploiting potential could be estimated only in the future.
5. Conclusion
Besides similarmethods regardingmiRNA extraction, profil-
ing, and validation, there are methodical differences between
studies, especially in internal controls and sample size, result-
ing in heterogeneous results. In principle, salivary miRNA
diagnostic methods seem feasible. However, in our opinion,
standardized criteria and protocols should be established
and followed exactly to obtain comparable results. Five
miRNAs related to inflammation are available, which may be
used as potential markers for periodontitis. However, their
detectability and expression in saliva and, accordingly, their
importance as noninvasive markers are questionable.
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